National Coverage Determination (NCD) for Transcatheter Aortic Valve Replacement (TAVR)
On May 1, 2012, the Centers for Medicare and Medicaid Services (CMS) issued a National Coverage Determination (NCD) covering TAVR under Coverage with Evidence Development (CED). When the procedure is furnished for the treatment of symptomatic aortic stenosis and according to an FDA-approved indication for use with an approved device, CED requires that each patient
be entered into a qualified national registry or participate in a qualifying clinical study.
Final
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: October 24, 2012
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.